Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04419298
Other study ID # CMR-CO
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 1, 2017
Est. completion date May 25, 2020

Study information

Verified date June 2020
Source Wonju Severance Christian Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Previous report showed that 37% of patients with moderate to severe carbon monoxide (CO) poisoning experienced a myocardial injury, defined as elevated cardiac enzyme [creatine kinase, CK-MB, and cardiac troponin I (TnI)] or ischemic electrocardiogram (ECG) change. In other study, 24% of the patients with the myocardial injury after CO poisoning died during a median follow-up of 7.6 years. The myocardial injury was the major predictor of mortality. In addition, in the Taiwanese nationwide population-based cohort study, CO poisoning itself reported as a higher risk of a major adverse cardiovascular event.

According to the previous study of investigators, among CO poisoned patients with myocardial injury, 74.4% of patients experienced CO-induced cardiomyopathy. All CO-induced cardiomyopathy recovered to normal status. In this situation, there is no definite approved reason why more cardiovascular events are occurred in CO poisoned patients with myocardial injury during long term follow-up period despite normalization of CO-induced elevated TnI and cardiac dysfunction.

Two image cases related to cardiac magnetic resonance imaging (CMR) in acute CO poisoning previously reported. One image case reported that patient had mildly depressed left ventricular (LV) systolic function with hypokinesis of the anterior wall and regional akinesis of the inferior wall on the transthoracic echocardiography performed during hospitalization and late gadolinium-enhancement (LGE) images of CMR demonstrated multiple focal areas of high signal consistent with myocardial necrosis or fibrosis. Another image case reported an image case that in CMR, inferolateral mid-wall myocardial fibrosis, which was defined as LGE, was present despite the setting of a completely normal echocardiogram at 4-month follow-up in CO poisoned patients.

Therefore, the investigators evaluate prevalence (frequency of LGE positive) and patterns (involved LV wall and range of LGE positive) of myocardial fibrosis (LGE positive) in acute CO-poisoned patients during acute (within seven days after CO exposure) and chronic phase (at 4-5 months after CO exposure) and whether LGE positive developed in acute phase have been changed through cardiac MRI performed at chronic phase. The investigators also evaluate LV ejection fraction and global longitudinal strain in transthoracic echocardiography performed at the ED (baseline) and within seven days (follow-up). The investigators also assessed the association between neurocognitive outcomes using the global deterioration scale (at 1, 6, and 12 months after CO exposure) and the presence of LGE positive.


Description:

In the US, carbon monoxide (CO) poisoning accounts for 1,300 deaths and 50,000 emergency department visits annually. Previous report showed that 37% of patients with moderate to severe CO poisoning experience a myocardial injury defined as elevated cardiac enzyme [creatine kinase, CK-MB, and cardiac troponin I (TnI)] or ischemic electrocardiogram (ECG) change. In other study, there was a mortality of 24% of patients during a median follow-up of 7.6 years. A mortality among the patients who experienced the myocardial injury was higher than patients without the myocardial injury. The death caused by cardiovascular problems occurred more among patients with a history of the myocardial injury (44% vs. 18%). The myocardial injury was the major predictor of mortality. In addition, in the Taiwanese nationwide population-based cohort study, a history of CO poisoning showed a higher risk of a major adverse cardiovascular event.

The investigators reported that myocardial injury (defined as elevated TnI or change of ischemic ECG) developed in 20% of CO poisoned patients and elevated TnI was normalized within 65.0 hours. According to previous study of the investigators, among CO poisoned patients with myocardial injury, 74.4% of patients experienced CO-induced cardiomyopathy. All CO-induced cardiomyopathy recovered to normal status. In this situation, there is no definite approved reason why more cardiovascular events are occurred in CO poisoned patients with myocardial injury during long term follow-up period despite normalization of CO-induced elevated TnI and cardiac dysfunction.

One case reported an image related to a CO poisoned patient with acute myocardial injury found by cardiac magnetic resonance imaging (CMR) with a normal coronary artery confirmed by coronary angiography. In that case, a patient showed that patient had mildly depressed left ventricular (LV) systolic function with hypokinesis of the anterior wall and regional akinesis of the inferior wall on the transthoracic echocardiography performed during hospitalization and late gadolinium-enhancement (LGE) images of CMR demonstrated multiple focal areas of high signal consistent with myocardial necrosis or fibrosis. Through this case, the investigators thought that CO poisoning might result in acute myocardial necrosis, demonstrating another type of myocardial injury that can be detected by CMR. In addition, Other case reported an image case that in cardiac MRI, inferolateral mid-wall myocardial fibrosis, which was defined as LGE, was present despite the setting of a completely normal echocardiogram at 4-month follow-up in a patient who experienced severe CO poisoning.

Mid-wall myocardial fibrosis has been reported in dilated cardiomyopathy (DCMP) of unclear origin. In a follow-up study of 101 consecutive patients with DCMP, mid-wall fibrosis (presented in 35% of patients) predicted a combined endpoint of all-cause mortality, cardiovascular hospitalization, and sudden cardiac death. Myocardial fibrosis has also been demonstrated in hypertrophic cardiomyopathy. The myocardial fibrosis has been linked to known markers for sudden cardiac death, although the independent prognostic value of CMR has yet to be determined.

Through above results, the investigators thought that the normal LV cardiac function may not reflect that there is no problem with the heart, and it could lead to myocardial fibrosis in the chronic phase. Myocardial damage seen through CMR may be related to the patient's prognosis. Therefore, the investigators evaluate prevalence (frequency of LGE positive) and patterns (involved LV wall and range of LGE positive) of myocardial fibrosis (LGE positive) in acute CO-poisoned patients during acute (within 7 days after CO exposure) and chronic phase (at 4-5 months after CO exposure) and whether LGE positive developed in the acute phase has been changed in cardiac MRI performed at chronic phase. The investigators also evaluate LV ejection fraction and global longitudinal strain in transthoracic echocardiography performed at the ED (baseline) and within seven days (follow-up). The investigators also assessed the association between neurocognitive outcomes using the global deterioration scale (at 1, 6, and 12 months after CO exposure) and the presence of LGE positive.


Recruitment information / eligibility

Status Completed
Enrollment 104
Est. completion date May 25, 2020
Est. primary completion date May 23, 2019
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria:

- Acute CO poisoning with myocardial injury, which was defined as elevated TnI (reference range < 0.045 ng/mL), within 24 hours after ED arrival.

Exclusion Criteria:

- Age <19 years

- No elevated TnI within 24 hours after ED arrival

- Cardiac arrest upon ED arrival or before taking a CMR

- Co-ingestion of cardiac toxic drugs

- Transferred patients without admission

- Declined to enrollment in the study

- Impossible CMR due to artificial device

- Calculated creatinine clearance (Ccr) < 30 mL/min

- Previous known history of hypersensitivity of gadolinium

- History of acute coronary syndrome, heart failure, or cardiomyopathy

- Patients who refuse CMR or fail to take a CMR although written informed consent was obtained

- Impossible of interpretation of CMR although CMR was taken

Study Design


Intervention

Diagnostic Test:
Cardiac MRI
Cardiac MRI be taken to acute CO poisoned patients with elevated TnI [during acute (within 7 days after CO exposure) and chronic phase (at 4-5 months after CO exposure)] TTE be taken to acute CO poisoned patients with elevated TnI [At the ED and during admission (within 7 days after CO exposure)]

Locations

Country Name City State
Korea, Republic of Wonju Severance Christian Hospital Wonju Gangwon

Sponsors (2)

Lead Sponsor Collaborator
Wonju Severance Christian Hospital National Research Foundation of Korea

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Late gadolinium enhancement (LGE) in CMR Prevalence (percent) of presence of LGE in CMR Within 7 days after acute CO poisoning
Primary LGE involved wall in CMR Injured left ventricular wall according to LGE in CMR Within 7 days after acute CO poisoning
Secondary LGE size in CMR Injury size according to LGE in CMR Within 7 days after acute CO poisoning
Secondary Change of LGE between first CMR and follow-up CMR Change of LGE between first CMR (within 7 days after CO exposure) and follow-up CMR (at 4-5 months after CO exposure) Within 7 days after CO exposure and at 4-5 months after CO exposure
Secondary LV ejection fraction (EF) of TTE performed at the ED Baseline LV EF of TTE performed at the ED Within 3 hours at the ED
Secondary LV global longitudinal strain (GLS) of TTE performed at the ED Baseline LV GLS of TTE performed at the ED Within 3 hours at the ED
Secondary LV EF of TTE performed during admission Follow-up LV EF of TTE performed during admission Within 7 days after CO exposure
Secondary LV GLS of TTE performed during admission Follow-up LV GLS of TTE performed during admission Within 7 days after CO exposure
Secondary Change of LV EF between ED TTE and follow-up TTE Change of LV EF between baseline TTE and follow-up TTE Within 3 hours at the ED and within 7 days after CO exposure
Secondary Change of LV GLS between ED TTE and follow-up TTE Change of LV GLS between baseline TTE and follow-up TTE Within 3 hours at the ED and within 7 days after CO exposure
Secondary Correlation between presence of LGE and poor neurocognitive outcome at 1, 6, and 12 months Correlation between presence of LGE and poor neurocognitive outcome [global deterioration scale (GDS) 4-7] evaluated by GDS at 1, 6, and 12 months after CO exposure GDS (minimum 1 - maximum 7) evaluated at 1, 6, and 12 months after CO exposure
See also
  Status Clinical Trial Phase
Terminated NCT03940651 - Cardiac and Renal Biomarkers in Arthroplasty Surgery Phase 4
Completed NCT01688648 - Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft N/A
Completed NCT04794062 - Myocardial Injury and Quality of Life After COVID-19
Recruiting NCT04750616 - NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial Phase 2
Recruiting NCT04615871 - Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19 Phase 2
Withdrawn NCT04139655 - Colchicine Prevents Myocardial Injury After Non-Cardiac Surgery Pilot Study N/A
Completed NCT05691764 - Effect of Cyclosporine and Remote Ischemic Preconditioning in Reperfusion Ischemia Injury on Tetralogy Fallot Patients With Correction Surgery N/A
Completed NCT04436016 - PeRiOperaTivE CardioproTection With Ivabradine in Non-cardiac Surgery Phase 4
Completed NCT05748691 - Switching From Cardiac Troponin I to T
Completed NCT03338504 - Determining the Mechanism of Myocardial Injury and Role of Coronary Disease in Type 2 Myocardial Infarction
Recruiting NCT03013634 - Protective Effects of Dexmedetomidine on Myocardial Injury During Liver Transplantation N/A
Completed NCT00007358 - Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus N/A
Recruiting NCT05714618 - MR Evidence of Cardiac Inflammation Post-Stroke
Recruiting NCT04624503 - Prognostic and Clinical Impact of Cardiovascular Involvement in Patients With COVID-19
Active, not recruiting NCT03339180 - Cardiac Injury in Patients With Influenza
Completed NCT03010839 - Cardiopulmonary Protective Effects of Modified Remote Ischaemic Preconditioning in Mitral Valve Replacement Surgery N/A
Recruiting NCT04743765 - HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial N/A
Enrolling by invitation NCT03253835 - Cardiac Blood Flow Patterns Associated With Left Ventricular Myocardial Damage
Completed NCT00817791 - Preconditioning With Hyperbaric Oxygen in Cardiovascular Surgery N/A
Completed NCT04149314 - The "Hypotension Prediction Index" in Patients Undergoing Lung Surgery N/A